Regional circulatory distribution of novel cardiac bio-markers and their relationships with haemodynamic measurements.

[1]  Hans L Hillege,et al.  Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction , 2010, Annals of medicine.

[2]  G. Rabinovich,et al.  Galectins: structure, function and therapeutic potential , 2008, Expert Reviews in Molecular Medicine.

[3]  J. Cleland,et al.  Determinants and prognostic value of pulmonary arterial pressure in patients with chronic heart failure. , 2010, European heart journal.

[4]  J. Struck,et al.  Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease. , 2008, Journal of the American College of Cardiology.

[5]  K. Miyamoto,et al.  Endothelial cells actively synthesize and secrete adrenomedullin. , 1994, Biochemical and biophysical research communications.

[6]  S. Anker,et al.  The importance of the gastrointestinal system in the pathogenesis of heart failure. , 2005, European heart journal.

[7]  Yigal M. Pinto,et al.  Galectin-3 Marks Activated Macrophages in Failure-Prone Hypertrophied Hearts and Contributes to Cardiac Dysfunction , 2004, Circulation.

[8]  S. Yusuf,et al.  Comparative Impact of Multiple Biomarkers and N-Terminal Pro-Brain Natriuretic Peptide in the Context of Conventional Risk Factors for the Prediction of Recurrent Cardiovascular Events in the Heart Outcomes Prevention Evaluation (HOPE) Study , 2006, Circulation.

[9]  A. Hoes,et al.  Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. , 2005, European heart journal.

[10]  J. Struck,et al.  Prognostic value of plasma midregional pro‐adrenomedullin and C‐terminal‐pro‐endothelin‐1 in chronic heart failure outpatients , 2009, European journal of heart failure.

[11]  Daniel Levy,et al.  Plasma natriuretic peptide levels and the risk of cardiovascular events and death. , 2004, The New England journal of medicine.

[12]  John G F Cleland,et al.  Prognostic significance of ultrasound-assessed jugular vein distensibility in heart failure , 2015, Heart.

[13]  J. Tardif,et al.  Reduced pulmonary clearance of endothelin-1 in pulmonary hypertension. , 1998, American heart journal.

[14]  J. Cleland,et al.  The in vitro stability of novel cardiovascular and sepsis biomarkers at ambient temperature , 2014, Clinical chemistry and laboratory medicine.

[15]  Juerg Schwitter,et al.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2010, European journal of heart failure.

[16]  T. Ishimitsu,et al.  Clinical studies on the sites of production and clearance of circulating adrenomedullin in human subjects. , 1994, Hypertension.

[17]  M. Assicot,et al.  High serum procalcitonin concentrations in patients with sepsis and infection , 1993, The Lancet.

[18]  N. Morgenthaler,et al.  Correlation of plasma copeptin and vasopressin concentrations in hypo-, iso-, and hyperosmolar States. , 2011, The Journal of clinical endocrinology and metabolism.

[19]  S. Anker,et al.  Pyrexia, procalcitonin, immune activation and survival in cardiogenic shock: the potential importance of bacterial translocation. , 1999, International journal of cardiology.

[20]  N. Freemantle,et al.  Relationship between plasma concentrations of N‐terminal pro brain natriuretic peptide and the characteristics and outcome of patients with a clinical diagnosis of diastolic heart failure: a report from the PEP‐CHF study , 2012, European journal of heart failure.

[21]  V. Hombach,et al.  Plasma brain natriuretic peptide and atrial natriuretic peptide concentrations correlate with left ventricular end‐diastolic pressure , 1993, Clinical cardiology.

[22]  Y. Wakiya,et al.  Relationship between plasma atrial natriuretic peptide levels and atrial pressure in man. , 1986, The Journal of clinical endocrinology and metabolism.

[23]  John G F Cleland,et al.  Revisiting a classical clinical sign: jugular venous ultrasound. , 2014, International journal of cardiology.

[24]  P. Ponikowski,et al.  Use of procalcitonin for the diagnosis of pneumonia in patients presenting with a chief complaint of dyspnoea: results from the BACH (Biomarkers in Acute Heart Failure) trial , 2012, European journal of heart failure.

[25]  J. Cleland,et al.  IVC diameter in patients with chronic heart failure: relationships and prognostic significance. , 2013, JACC. Cardiovascular imaging.

[26]  L. Rochette,et al.  P4243 | SPOTLIGHT 2013 Urinary and plasma galectin-3 in heart failure - insights in renal handling , 2013 .

[27]  D. Stewart,et al.  Human pulmonary circulation is an important site for both clearance and production of endothelin-1. , 1996, Circulation.

[28]  K. Kangawa,et al.  Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. , 1993, Biochemical and biophysical research communications.

[29]  J. Cleland,et al.  Global longitudinal strain in patients with suspected heart failure and a normal ejection fraction: does it improve diagnosis and risk stratification? , 2013, The International Journal of Cardiovascular Imaging.